Erratum to: Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs: Prescribing pattern of antipsychotic drugs in Europe during 1996-2010 (British Journal of Clinical Pharmacology, (2016), 82, 2, (487-497), 10.1111/bcp.12955);Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs

British Journal of Clinical Pharmacology

Volumn 83, Issue 6, 2016, Pages 487-497

  Oteri, Alessandro ^a,b   Mazzaglia, Giampiero ^c   Pecchioli, Serena ^c,d   Molokhia, Mariam ^e   Ulrichsen, Sinna Pilgaard ^f   Pedersen, Lars ^f   Poluzzi, Elisabetta ^g   De Ponti, Fabrizio ^g   Garbe, Edeltraut ^h   Schink, Tania ^h   Herings, Ron ⁱ   Bezemer, Irene D ⁱ   Sturkenboom, Miriam C J M ^a   Trifirò, Gianluca ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MESSINA   (Italy)

^c Health Search   (Italy)

^d Regional Agency for Healthcare Services of Tuscany   (Italy)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

ⁱ PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

antipsychotic drugs; population based study; torsadogenic potential

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; HALOPERIDOL; ILOPERIDONE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DENMARK; DRUG SAFETY; EUROPE; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; UNITED KINGDOM; VERY ELDERLY;

EID: 84978674801     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13283     Document Type: Erratum

References (32)

1. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703–11.
2. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161–7.
3. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070.
4. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med 2005; 165: 696–701.
5. Committee on Safety of Medicines. Cardiotoxic effects of pimozide. Curr Probl Pharmacovig 1990; 29: 1.
6. Committee on Safety of Medicines. Drug-induced prolongation of the QT interval. Curr Probl Pharmacovig 1996; 22: 2.
7. Royal College of Psychiatrists. The association between antipsychotic drugs and sudden death: report of the working group of the Royal College of Psychiatrists' Psychopharmacology Sub-Group, CR57. London: Royal College of Psychiatrists, 1997.
8. National Institute for Clinical Excellence. The short-term management of disturbed (violent) behaviour in adult psychiatric inpatient settings. First Consultation document. London: NICE; 2004.
9. Committee on Safety of Medicines. Suspension of availability of Serdolect (sertindole). London: Department of Health; 1998.
10. Medicines and Healthcare Products Regulatory Agency (MHRA). Restricted re-introduction of the atypical antipsychotic sertindole (Serdolect); 2001. Available at: http://webarchive.nationalarchives.gov.uk/20110505062033/http://www.mhra.gov.uk/PrintPreview/DefaultSP/CON019523 (last accessed 11 August 2015).
11. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010; 122: 345–55.
12. Medicines and Healthcare Products Regulatory Agency (MHRA). Restricts the use of thioridazine. MHRA Press Release 2000/0734. London: MHRA; 2000.
13. Food and Drug Administration (FDA). Information for healthcare professionals: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). FDA; 2007. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm (last accessed 11 August 2015)
14. Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, et al. on behalf of Investigators of the Aritmo Consortium. Sudden cardiac and sudden unexpected death related to antipsychotics: a meta-analysis of observational studies. Clin Pharmacol Ther 2016; 99: 306–14.
15. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011; 168: 193–201.
16. Cáceres MC, Peñas-Lledó EM, de la Rubia A, Llerena A. Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. Eur J Clin Pharmacol 2008; 64: 73–6.
17. Santamaría B, Pérez M, Montero D, Madurga M, de Abajo FJ. Use of antipsychoticagents in Spain through 1985–2000. Eur Psychiatry 2002; 17: 471–6.
18. Trifirò G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999–2002. Eur J Clin Pharmacol 2005; 6: 47–53.
19. Arizona CERT. Center for Education and Research on Therapeutics. Available at: https://www.crediblemeds.org/new-drug-list/ (last accessed 11 August 2015).
20. Trifiro G, Fourrier-Reglat A, Sturkenboom MC, Díaz Acedo C, van Der Lei J, EU-ADR Group. The EU-ADR project: preliminary results and perspective. Stud Health Technol Inform 2009; 148: 43–9.
21. Holstiege J, Schink T, Molokhia M, Mazzaglia G, Innocenti F, Oteri A, et al. Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: a population-based cohort study. BMC Pediatr 2014; 14: 174.
22. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 2003; 56: 569–75.
23. Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One 2013; 8: e81208.
24. Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013; 36: 467–79.
25. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55–61.
26. Agenzia Italiana del Farmaco. Determinazione 28 febbraio 2007. Available at: http://www.gazzettaufficiale.biz/atti/2007/20070060/07A02238.htm (last accessed 11 August 2015).
27. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170: 96–103.
28. Trifirò G, Sini G, Sturkenboom MC, Vanacore N, Mazzaglia G, Caputi AP, et al. Prescribing pattern of antipsychotic drugs in the Italian general population 2000–2005: a focus on elderly with dementia. Int Clin Psychopharmacol 2010; 25: 22–8.
29. Sanfélix-Gimeno G, Cervera-Casino P, Peiró S, López-Valcarcel BG, Blázquez A, Barbera T. Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain. Drug Saf 2009; 32: 1075–87.
30. Garrison GD, Levin GM. Factors affecting prescribing of the newer antidepressants. Ann Pharmacother 2000; 34: 10–4.
31. Oteri A, Trifirò G, Gagliostro MS, Tari DU, Moretti S, Bramanti P, et al. Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol 2010; 70: 514–22.
32. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35.